Phylogenetic Analysis of a Human Isolate from the 2000 Israel West Nile virus Epidemic

Thomas Briese,* Andrew Rambaut,† Melissa Pathmajeyan,* Jihad Bishara,‡ Miriam Weinberger,‡ Silvio Pitlik,‡ and W. Ian Lipkin*

Specimens from a patient of the 2000 Israel West Nile virus epidemic were analyzed by reverse transcription-polymerase chain reaction. Products corresponding to E, NS3, and NS5 sequences were amplified from cerebellar but not from cortical samples. Phylogenetic analyses indicated a closer relationship of this isolate to 1996 Romanian and 1999 Russian than to 1998-99 Israeli or 1999 New York isolates.

West Nile fever is typically a mild febrile illness characterized by headache, myalgias, lymphadenopathy, and a maculopapular rash; West Nile fever occurs sporadically throughout endemic areas of northeastern Africa and tropical Asia (1-5). The causative agent, West Nile virus (WNV), is a member of the genus Flavivirus (family Flaviviridae), which is grouped together with Alfuy virus, Cacibaculovirus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Usutu virus, and Yaounde virus in the Japanese encephalitis virus antigenic complex (6,7). Two different lineages (I and II) of WNV are characterized genetically (8). Whereas lineage II viruses are isolated in endemic areas, lineage I viruses are isolated during epidemic outbreaks of WNV infection and may cause severe encephalitis in the elderly or immunosuppressed persons. Epidemics of West Nile fever were first reported in the 1950s in Israel (2) and the 1970s in South Africa (9). Sites of notable recent outbreaks include Romania (1996, 1997), Italy (1998), Russia (1999), France (2000), United States (1999, 2000) and Israel (2000) (5,10). Sequence analysis of the WNV responsible for the United States outbreak in 1999 (1999, 2000) and Israel (2000) (5,10). Sequence analysis of the WNV responsible for the United States outbreak in 1999 (1999, 2000) and Israel (2000) (5,10) showed a closer phylogenetic relationship to a WNV isolated from a goose in Israel in 1998 (WNV-ISR1998) (11,12).

WNV is transmitted mainly by mosquito vectors, although it has also been isolated in several tick species (3,5,13). Birds are an important WNV reservoir. In several avian species, virus replication generates serum titers sufficient to sustain arthropod transmission (4,5). Birds, during seasonal migrations, are also believed to be instrumental in the geographic spread of WNV (3-5,14). The virus is only occasionally transmitted to humans or other mammals. Viremia in mammals is low level; thus, mammals are considered to be dead-end hosts.

The Study

From July through November 2000, a WNV epidemic occurred in central and northern Israel. More than 430 people were diagnosed with WNV infection; 29 of these patients had fatal encephalitis. We report phylogenetic analysis of WNV sequences isolated from the brain of an encephalitis patient from the 2000 Israel epidemic.

A 72-year-old woman with a history of recurrent meningioma of the sphenoidal ridge, dementia, and depression was hospitalized because of fever and general deterioration of 5 days’ duration. On admission, the patient was responsive only to painful stimuli and had generalized muscle stiffness and limb tremors. Clinical and laboratory values were consistent with viral encephalitis; thus, the patient was initially treated with intravenous acyclovir for presumptive herpes simplex encephalitis. When polymerase chain reaction (PCR) analysis of cerebrospinal fluid (CSF) showed no evidence of herpes simplex virus infection, and WNV antibodies were detected in serum and CSF, acyclovir was discontinued and ribavirin was initiated at an oral dosage of 2.4 g per day. The patient’s clinical status continued to deteriorate with aspiration pneumonia and intermittent generalized seizures. Intravenous immunoglobulin was added (35 g/d for 2 days) without improvement. Approximately one month after onset of illness, the patient died of respiratory failure.

Postmortem examination of the brain showed multiple meningiomas, generalized atrophy, and surgical resection of the right parietal lobe. Histology was remarkable for neurofibrillary plaques consistent with Alzheimer’s disease, and scattered microglial nodules and perivascular lymphocytic inflammation in the medulla, pons, and midbrain were consistent with viral encephalitis.

RNA was extracted from frontal cortex and cerebellum with TRI- Reagent (Molecular Research Center, Cincinnati, OH). Four micrograms of total RNA from each brain region were used as a template for reverse transcription-polymerase chain reaction (RT-PCR) with primer sets representing three regions of sequence conservation in flavivirus genomes: NS3-1 (EDL/Fla-U5004, 5’-GGA ACD TCM GGH TCN CCH AT and EDL/Fla-L5457, 5’-GTG AAR TGD GCY TCR TCC AT), NS3-1.1 (EDL/Fla-U9093, 5’-AGY MGR GCH ATH TGG TWY ATG TGG and EDL/Fla-L9279, 5’-TCC CAV CCD GCK GTR TCA TC), and NS3-2 (EDL/Fla-U9954, 5’-GSS AAA KCH TAY GCN ATG TGG and EDL/Fla-L10098 5’-AGC ATR TCT TCH GTN GTC ATC CA) (15,16). Amplification products were obtained with RNA derived from the cerebellum in reactions with all three primer sets; no amplification products were obtained with RNA from the cortex. These amplification products were cloned into the

*University of California at Irvine, Irvine, California, USA; †University of Oxford, Oxford, UK; and ‡Rabin Medical Center–Beilinson Campus, Petah Tikva, Israel

DISPATCHES

Emerging Infectious Diseases • Vol. 8, No. 5, May 2002
patients were 75 years to 80 years of age, 3 male, 1 female, the 1999 New York City outbreak (data not shown; New York studies performed with brain materials from four patients of bromide-stained gels was reduced in comparison with similar

The 1999 New York City outbreak (Table).

ies/200 ng RNA in specimens analyzed from the New York Israeli sample, compared with a range of 20 to 7000 copies/200 ng RNA in specimens analyzed from the New York City outbreak (Table). However, since the virus load of the sample from Israel was within the range of virus loads observed with the New York samples, this result for a single Israeli sample may not indicate a strain difference. Quantitative analysis was restricted to the NS5 target because no signal was obtained with primer/probe set pNS5 (fwd - 2 mismatches, probe – 3 mismatches, rev - 3 mismatches; given above in lower case). Sensitivity was not substantially reduced in assays with primer/probe set pNS5, which had one mismatch in the primer and probe oligonucleotides (fwd - 2 mismatches, rev, 5´-AGG GTa GCA TGa CA), because of point mutations in WNV-IS98St1, ISR-99Goo, and ISR-99Gull [Figure], but similar to the human isolate. Nonetheless, precedent exists for implicating more than one genotypic variant in a WNV outbreak.

Sequence analysis of the cloned NS3 and NS5 gene fragments indicated similarity to completely sequenced Romanian and Russian WNV isolates WNV-RO97-50-1996 and WNV-RUS-VLG4-1999, respectively; thus, to facilitate detailed phylogenetic analysis, E gene sequence from the Israeli human brain sample was amplified. An E gene sequence of 1,509 nucleotides (GenBank accession number AF394217) was amplified from total RNA by using GeneChoice UNIPOL polymerase (PGC Scientific, Gaithersburg, MD) and primers

Table. Real Time reverse transcription-polymerase chain reaction (RT-PCR) analysis of RNA extracts from 2000 Israel West Nile patient specimens using primer set NY1999-NS5

| NS5 standard NY1999 | Armored RNA | Armored RNA extract | NY1999 specimens | NS5 standard ISR2000 | ISR2000 specimens |
|---------------------|-------------|---------------------|------------------|----------------------|------------------|
| Amount<sup>a</sup> | C<sub>T</sub><sup>b</sup> | Dil<sup>c</sup> | Amount<sup>d</sup> | Dil<sup>e</sup> | Amount<sup>d</sup> | Patient no. | C<sub>T</sub> | Amount<sup>d</sup> | Amount<sup>f</sup> | C<sub>T</sub> | Sample | C<sub>T</sub> | Amount<sup>f</sup> |
| 2.5x10<sup>6</sup> | 16.4 | 1:10<sup>1</sup> | 4.5x10<sup>6</sup> | 1:10<sup>1</sup> | 4.4x10<sup>5</sup> | 1 | 29.3 | 6.9x10<sup>2</sup> | 2.5x10<sup>6</sup> | 16.5 | cereb. | 31.1 | 1.4x10<sup>2</sup> |
| 2.5x10<sup>5</sup> | 20.0 | 1:10<sup>2</sup> | 3.4x10<sup>5</sup> | 1:10<sup>2</sup> | 4.0x10<sup>4</sup> | 2 | 25.6 | 7.3x10<sup>3</sup> | 2.5x10<sup>5</sup> | 20.0 | cortex | 36.4<sup>b</sup> | 1.9x10<sup>0</sup> |
| 2.5x10<sup>4</sup> | 23.6 | 1:10<sup>3</sup> | 3.1x10<sup>4</sup> | 1:10<sup>3</sup> | 4.3x10<sup>3</sup> | 3 | 30.0 | 4.6x10<sup>2</sup> | 2.5x10<sup>4</sup> | 23.1 | |
| 2.5x10<sup>3</sup> | 27.2 | 1:10<sup>4</sup> | 3.1x10<sup>3</sup> | 1:10<sup>4</sup> | 6.0x10<sup>2</sup> | 5 | 34.8 | 2.3 x10<sup>1</sup> | 2.5x10<sup>3</sup> | 26.7 | |
| 2.5x10<sup>2</sup> | 31.1 | 1:10<sup>5</sup> | 3.4x10<sup>2</sup> | 1:10<sup>5</sup> | 9.8x10<sup>1</sup> | 2.5x10<sup>2</sup> | 30.3 | |
| 2.5x10<sup>1</sup> | 34.9 | 1:10<sup>6</sup> | 3.1x10<sup>1</sup> | 1:10 | 2.1x10<sup>0</sup> | 2.5x10<sup>1</sup> | 34.1 | |
| 2.5x10<sup>0</sup> | 36.8<sup>b</sup> | 1:10<sup>7</sup> | 3.0x10<sup>0</sup> | 1:10<sup>7</sup> | n.d<sup>f</sup> | 2.5x10<sup>0</sup> | 37.3<sup>h</sup> | |
| 0 >45 | 0 | 0 | 0 | 0 | >45 | 0 | 0 |

<sup>a</sup> Plasmid DNA p88-D-21 was quantitated spectrophotometrically, and dilutions containing the indicated copy number of target sequence were added to each polymerase chain reaction (PCR) assay.

<sup>b</sup> C<sub>T</sub>, Cycle number at which signal crosses threshold.

<sup>c</sup> Armored RNA West Nile virus (HNY1999) standard (Ambion, Austin, TX) was diluted 1:10, boiled, reverse transcribed, and then diluted to result in amounts per PCR assay equivalent to the indicated dilution of the stock (5 µL).

<sup>d</sup> Amount calculated based on calibration curve obtained with NS5 Standard NY1999 (column 1).

<sup>e</sup> Dilutions of Armored RNA West Nile virus (HNY1999) standard (Ambion) were extracted with TRI-Reagent (Molecular Research Center, Cincinnati, OH) and then subjected to RT-PCR to result in amounts per assay equivalent to the indicated dilution of the stock (5 µL).

<sup>f</sup> Plasmid DNA pISR-Dfrag-D6 was quantitated spectrophotometrically, and dilutions containing the indicated copy number of target sequence were added to each PCR assay.

<sup>g</sup> Amount calculated based on calibration curve obtained with NS5 Standard ISR2000 (column 5).

<sup>h</sup> Poisson effects take place at low template concentration; duplicate assay deviations: 36.2 / 37.4, NY1999; 6.0 x10<sup>0</sup> / 0, armored RNA; 37.4 / 37.1, ISR2000; and 36.4 / >45, cortex.

<sup>i</sup> n.d., not determined.
During the 1999 outbreak in Volgograd, Russia, two different genotypes were isolated: WNV-RUS-ASTR986-1999 (similar to 1997/98/99 Israeli and the WNV-NY1999 isolates, genotype lineage 1 subtype 2a) and WNV-VLG22889/WNV-RUS-VLG4-1999 (similar to WNV-ISR-hISR2000, subtype 2b [Figure]) (19). Indeed, even more divergent genotypes were identified during the 1996-97 WNV outbreak in Romania (WNV-RO97-50-1996 similar to WNV-ISR-hISR2000, genotype lineage 1 subtype 2b; WNV-RO96-1030-1996 and WNV-ROM96(0334)-1996, belonging to a different subtype, subtype 1 [Figure]) (20). The fact that no such divergence of genotypes of WNV isolates was observed during the 1999 New York epidemic (Figure) was interpreted as being compatible with a single, new introduction of this virus to the Western Hemisphere. While this manuscript was under review, another group reported WNV sequences from four patients of the 2000 Israel outbreak: two isolates most closely related to WNV-RO97-50-1996 and two identical to the WNV-NY1999 isolates (21). Analysis of additional isolates from the Israel 2000 and other outbreaks, including isolates obtained in 2000, 2001, and subsequent years in the USA, will be required to establish the extent to which avian migration and viral mutation contribute to the epidemiology of WNV-related disease.

This study was supported by the National Institutes of Health (NS-29425).

Dr. Briese is associate director of the Emerging Diseases Laboratory and assistant professor at the University of California, Irvine. In summer 2002, he will join the faculty in the Mailman School of Public Health at Columbia University as an associate professor of Epidemiology.

References

1. Goldblum N, Sterk VV, Paderski B. West Nile fever. The clinical features and the isolation of West Nile virus from the blood of nine human cases. Am J Hyg 1954;59:89-103.

2. Marberg K, Goldblum N, Sterk VV, Jasinska-Klingberg W, Klingberg MA. The natural history of West Nile fever. I. Clinical observations during an epidemic in Israel. Am J Hyg 1956:64.259-65.

3. Taylor RM, Work TH, Hurlbut HS, Rizk F. A study of the ecology of West Nile virus in Egypt. Am J Trop Med Hyg 1956;5:579-620.

4. Monath TP, Heinz FX. Flaviviruses. In: Fields BN, Knipe DM, Howley PM, editors. Virology. Philadelphia: Lippincott-Raven; 1996. p.961-1034.

5. Hubálek Z, Halouzka J. West Nile fever—a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 1999;5:643-50.

6. Marburg K, Goldblum N, Sterk VV, Jasinska-Klingberg W, Klingberg MA. The natural history of West Nile fever. I. Clinical observations during an epidemic in Israel. Am J Hyg 1956;64.259-65.

7. Calisher CH. Antigenic classification and taxonomy of flaviviruses (family Flaviviridae) emphasizing a universal system for the taxonomy of viruses causing tick-borne encephalitis [see comments]. Acta Virol 1988;32:469-76.

8. Berthet FX, Zeller HG, Drouet MT, Rauzier J, Digoutte JP, Deubel V. Studies on the envelope protein gene of Euro-African West Nile viruses. J Gen Virol 1997;78:2293-7.

9. Goldblum N, Sterk VV, Paderski B. West Nile fever. The clinical features and the isolation of West Nile virus from the blood of nine human cases. Am J Hyg 1954;59:89-103.

10. Marberg K, Goldblum N, Sterk VV, Jasinska-Klingberg W, Klingberg MA. The natural history of West Nile fever. I. Clinical observations during an epidemic in Israel. Am J Hyg 1956:64.259-65.

11. Taylor RM, Work TH, Hurlbut HS, Rizk F. A study of the ecology of West Nile virus in Egypt. Am J Trop Med Hyg 1956;5:579-620.

12. Marburg K, Goldblum N, Sterk VV, Jasinska-Klingberg W, Klingberg MA. The natural history of West Nile fever. I. Clinical observations during an epidemic in Israel. Am J Hyg 1956:64.259-65.

13. Taylor RM, Work TH, Hurlbut HS, Rizk F. A study of the ecology of West Nile virus in Egypt. Am J Trop Med Hyg 1956;5:579-620.

14. Marburg K, Goldblum N, Sterk VV, Jasinska-Klingberg W, Klingberg MA. The natural history of West Nile fever. I. Clinical observations during an epidemic in Israel. Am J Hyg 1956:64.259-65.

15. Taylor RM, Work TH, Hurlbut HS, Rizk F. A study of the ecology of West Nile virus in Egypt. Am J Trop Med Hyg 1956;5:579-620.
9. McIntosh BM, Jupp PG, Dos Santos I, Meenehan GM. Epidemics of West Nile and Sindbis viruses in South Africa with Culex (Culex) univittatus Theobald as vector. S Afr J Sci 1976;72:295-300.
10. Jordan I, Briese T, Fischer N, Lau JY-N, Lipkin WI. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000;182:1214-7.
11. Jia XY, Briese T, Jordan I, Rambaut A, Chi HC, Mackenzie JS, et al. Genetic analysis of West Nile New York 1999 encephalitis virus. Lancet 1999;354:1971-2.
12. Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, Steele K, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999;286:2333-7.
13. Hurlbut HS. West Nile virus infection in arthropods. Am J Trop Med Hyg 1956;5:76-85.
14. Hoogstraal H, Kaiser MN, Gaber S, Traylor MA, Guindy E. Ticks (Ixodoidea) on birds migrating from Africa to Europe and Asia. Bull World Health Organ 1961;24:197-212.
15. Lipkin WI, Briese T. West Nile-like virus: PCR primers and protocols. ProMed. October 13, 1999. Accessed at: http://www.promedmail.org, archive number: 19991013.1826.
16. Briese T, Jia XY, Huang C, Grady LJ, Lipkin WI. Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis. Lancet 1999;354:1261-2.
17. Briese T, Glass WG, Lipkin WI. Detection of West Nile virus sequences in cerebrospinal fluid. Lancet 2000;355:1614-5.
18. Miller BR, Nasci RS, Godsey MS, Savage HM, Lutwama JJ, Lanciotti RS, et al. First field evidence for natural vertical transmission of West Nile virus in Culex univittatus complex mosquitoes from Rift Valley province, Kenya. Am J Trop Med Hyg 2000;62:240-6.
19. Lvov DK, Butenko AM, Gromashevsky VL, Larichev VP, Gaidamovich SY, Vysheimsky OL, et al. Isolation of two strains of West Nile virus during an outbreak in southern Russia, 1999. Emerg Infect Dis 2000;6:373-6.
20. Savage HM, Ceianu C, Nicolescu G, Karabatsos N, Lanciotti R, Vladimirescu A, et al. Entomologic and avian investigations of an epidemic of West Nile fever in Romania in 1996, with serologic and molecular characterization of a virus isolate from mosquitoes. Am J Trop Med Hyg 1999;61:600-11.
21. Hindiyeh M, Shulman LM, Mendelson E, Weiss L, Grossman Z, Bin H. Isolation and characterization of West Nile virus from the blood of viremic patients during the 2000 outbreak in Israel. Emerg Infect Dis 2001;7:748-50.

Address for correspondence: T. Briese, Emerging Diseases Laboratory, Departments of Neurology, Microbiology and Molecular Genetics, 3107 Gillespie Neuroscience Building, University of California at Irvine, Irvine, California 92697-4292, USA; fax: 949-824-1229; e-mail: tbriese@uci.edu